Effects of animal-assisted therapy on dental anxiety, behavior, and perceptions in young pediatric patients: a blinded randomized controlled trial.

BACKGROUND

Between 6 and 22% of children are affected by dental anxiety. Dental anxiety is a significant barrier to dental care and is associated with dental avoidance and negative oral health outcomes. Pharmacological methods of anxiety management are costly, carry risks of adverse outcomes, and may not be acceptable to some families. Alternative non-pharmacological methods are needed for the safe and effective delivery of dental care. Although there is an abundance of literature regarding animal-assisted therapy (AAT) in medicine, only preliminary studies on AAT exist in dentistry. To identify optimal outcome measures for evaluating AAT in pediatric dental contexts, a randomized controlled trial protocol was developed.

METHODS

A prospective randomized controlled trial protocol was developed to examine the impact of AAT on objective (heart rate, salivary stress and pain markers, and observational coding) and subjective self-reported measures of anxiety, pain, and dental expectations in pediatric patients. The study is designed to enroll 180 pediatric patients (4-8 years old), randomized into three arms (n = 60 per arm) with stratification by age (< 6.5 vs ≥ 6.5) and gender (block size = 4). Two therapy protocols (+ Short AAT and + Long AAT exposures) will be compared relative to an active control (coloring a dog picture) during a diagnostic dental visit consisting of an oral exam, dental cleaning, and simulated bitewing intraoral radiographs.

DISCUSSION

This study will provide information on optimal outcome measures to evaluate the impact of AAT on dental anxiety and behavior in pediatric dental patients. Determining the effects of AAT in pediatric dental care may provide a safe, non-pharmacological method of anxiety and behavior management, with broad translational impact.

TRIAL REGISTRATION

This trial was registered on ClinicalTrials.gov with number NCT05464888, on 15 July 2022 (first submitted to ClinicalTrials.gov) and 19 July 2022 (first posted to ClinicalTrials.gov).